Compare BMEA & TUSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMEA | TUSK |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oilfield Services/Equipment |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.1M | 127.7M |
| IPO Year | 2021 | 2016 |
| Metric | BMEA | TUSK |
|---|---|---|
| Price | $1.40 | $3.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $9.83 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 426.7K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 69.19 | ★ 102.32 |
| EPS | N/A | ★ 0.11 |
| Revenue | N/A | ★ $44,292,000.00 |
| Revenue This Year | N/A | $383.90 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $30.09 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.87 | $1.72 |
| 52 Week High | $3.07 | $3.60 |
| Indicator | BMEA | TUSK |
|---|---|---|
| Relative Strength Index (RSI) | 45.33 | 63.36 |
| Support Level | $1.23 | $2.09 |
| Resistance Level | $1.45 | $3.54 |
| Average True Range (ATR) | 0.10 | 0.27 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 47.57 | 60.42 |
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Mammoth Energy Services Inc is an integrated energy services company engaged in providing products and services to enable the exploration and development of North American onshore unconventional oil and natural gas reserves as well as the construction and repair of the electric grid for private utilities, public investor-owned utilities, and co-operative utilities through infrastructure services businesses. The company had three reportable segments, which includes rental services, infrastructure services, natural sand proppant services, accommodation services, and drilling services.